Could a simple injection make thin gums thicker?
NCT ID NCT07682259
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether injecting a mix of concentrated platelet-rich fibrin (C-PRF) and hyaluronic acid can thicken thin gums better than C-PRF alone. Twenty healthy adults with naturally thin gums will receive both treatments on different sides of their mouth. The goal is to see which approach increases gum thickness and width more over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Concentrated Platelet-Rich Fibrin (C-PRF) and Hyaluronic Acid
- What this could lead to
- If successful, this could offer a simple injection-based method to thicken thin gums, potentially reducing gum recession and improving oral health.
- What could go wrong
- This is a small, early-stage trial with only 20 participants, so results may not apply to everyone. The treatment may not work as well as hoped, and risks like swelling or infection are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Systemically healthy male or female adults aged 20 to 40 years. 2. Non-smoker. 3. Presence of a clinically thin gingival phenotype (gingival thickness ≤ 1.0 mm) at the targeted surgical sites. 4. Presence of bilateral homologous teeth (e.g., both maxillary canines, or both mandibular first premolars) exhibiting the same thin gingival phenotype to allow for paired test and control sites within the same oral cavity. 5. Patients must demonstrate a high standard of oral hygiene, defined as a full-mouth plaque score and full-mouth bleeding score of ≤ 10% following initial cause-related therapy. 6. Willingness to comply with the 6-month follow-up schedule and provide written informed consent before enrollment. Exclusion Criteria: 1. Any systemic disease or condition known to compromise wound healing or alter immune response (e.g., uncontrolled diabetes mellitus, autoimmune disorders, bleeding dyscrasias). 2. Current or recent use of medications known to induce gingival enlargement (e.g., phenytoin, cyclosporine, calcium channel blockers) or medications affecting blood coagulation and platelet function (e.g., anticoagulants) within last 10 days of the procedure. 3. Active periodontitis, defined by probing depths \> 3 mm or bleeding on probing at the designated experimental sites 4. Any previous history of mucogingival surgery, soft tissue grafting, or local trauma at the selected test or control sites. 5. Current tobacco smoking or vaping, due to its well-documented detrimental effects on local angiogenesis and soft tissue grafting outcomes. 6. Pregnant or lactating females, due to hormonal fluctuations that can temporarily alter the gingival tissue response and capillary permeability.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thin gingival phenotype are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Al-mustansiriyah university
Baghdad, Alresafa, 10011, Iraq